



OPEN ACCESS

EDITED AND REVIEWED BY
Anne Haney Cross,
Washington University in St. Louis,
United States

*CORRESPONDENCE
Regina Berkovich
✉ reginaberkovichmd@gmail.com

†These authors have contributed equally to
this work

RECEIVED 09 April 2025
ACCEPTED 26 May 2025
PUBLISHED 13 June 2025

CITATION
Berkovich R, Calkwood J, Crayton H, Erwin A,
Faissner S, Gold R, Katz J and Leekoff M
(2025) Corrigendum: Switching
to ublituximab from prior anti-
CD20 monoclonal antibody
therapy: a case report series.
Front. Immunol. 16:1609054.
doi: 10.3389/fimmu.2025.1609054

COPYRIGHT
© 2025 Berkovich, Calkwood, Crayton, Erwin,
Faissner, Gold, Katz and Leekoff. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Regina Berkovich^{1*†}, Jonathan Calkwood^{2†}, Heidi Crayton^{3†},
April Erwin^{4†}, Simon Faissner^{5†}, Ralf Gold^{5†}, Joshua Katz^{6†}
and Mark Leekoff^{7†}

¹Regina Berkovich MD, PhD Inc (MS Center and Research Institute), West Hollywood, CA, United States,

²Department of Neurology, Minnesota Center for Multiple Sclerosis, Plymouth, MN, United States,

³Department of Neurology, MS Center of Greater Washington, Vienna, VA, United States, ⁴Department of Neurology, Rocky Mountain MS Clinic, Salt Lake City, UT, United States, ⁵Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany, ⁶Department of Neurology, The Elliot Lewis Center, Wellesley, MA, United States, ⁷Atlantic Medical Group Multiple Sclerosis Comprehensive Care Center, Bridgewater, NJ, United States

KEYWORDS

anti-CD20, B-cell depletion, disability, magnetic resonance imaging, multiple sclerosis, ocrelizumab, rituximab, ublituximab

A Corrigendum on:

Switching to ublituximab from prior anti-CD20 monoclonal antibody
therapy: a case report series

by Berkovich R, Calkwood J, Crayton H, Erwin A, Faissner S, Gold R, Katz J and Leekoff M
(2025). *Front. Immunol.* 16:1527102. doi: 10.3389/fimmu.2025.1527102

In the published article, there was an error in affiliation 1. Instead of “Berkovich MS Center and Research Institute, West Hollywood, CA, United States,” it should be “Regina Berkovich MD, PhD Inc (MS Center and Research Institute), West Hollywood, CA, United States.”

Also, there was an error in **Figure 1**, **Figure 3**, and **Figure 4** as published. The y-axis titles of these figures contained a typo listing the unit of measure as “cells/¼ L”; the correct unit of measure is “cells/μL.” The corrected **Figure 1**, **Figure 3**, and **Figure 4** and their captions appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 1
CD19+ counts in Case 1 during ocrelizumab treatment and after switch to ublituximab treatment. Ocrelizumab treatment was initiated in July 2019, with last ocrelizumab dose in October 2022. Ublituximab treatment was started in March 2023, with robust B-cell depletion (3 cells/μL) observed at 1 week after first ublituximab dose.




FIGURE 3
CD19+ counts in Case 2 during ocrelizumab treatment and after switch to ublituximab treatment. Ocrelizumab treatment was initiated in October 2019, with last ocrelizumab dose received in June 2022. The individual skipped the December 2022 ocrelizumab infusion with the intent to switch to ublituximab and initiated ublituximab treatment in March 2023, with complete B-cell depletion observed at the subsequent preinfusion blood collections.

